Dr Reddy’s Posts Surprise Q3 Loss With NuvaRing Write-Off
Main Markets Strong But Compliance Issues Linger
Dr Reddy’s Laboratories reported an unexpected third-quarter consolidated net loss after taking a $156m charge related to its generic version of the NuvaRing contraceptive. However, the company’s shares jumped on a robust underlying performance that was praised by analysts.
